Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

Sponsor
Bristol-Myers Squibb
Study ID
NCT07526961
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will review medical records from hospitals in Poland to describe the demographics and baseline clinical characteristics of adults with advanced non-small cell lung cancer who received first-line nivolumab plus ipilimumab with chemotherapy in routine care between 01 January 2023 and 31 December 2023. The study will also describe treatment patterns and clinical outcomes, associated with immunotherapy.

Key Dates

Start date
Dec 1, 2025
Status verified
Mar 2026
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026

Study Design

Enrollment
240 participants (actual)

Arms

  • Arm: Overall Study Population
    Adults with inoperable locally advanced or metastatic non-small cell lung cancer with programmed death-ligand 1 (PD-L1) tumor proportion score \<50% who were prescribed first-line nivolumab plus ipilimumab plus chemotherapy in the Polish Drug Program between 01 January 2023 and 31 December 2023 at participating hospitals in Poland.

Primary Outcome Measure

Second-line systemic anticancer treatment prescribed after progression/discontinuation of first-line therapy [ Time Frame: Up to 26 months ]

Related Studies